Qutenza

RSS

capsaicin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Qutenza. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Qutenza.

This EPAR was last updated on 11/10/2021

Authorisation details

Product details
Name
Qutenza
Agency product number
EMEA/H/C/000909
Active substance
capsaicin
International non-proprietary name (INN) or common name
capsaicin
Therapeutic area (MeSH)
Neuralgia
Anatomical therapeutic chemical (ATC) code
N01BX04
Publication details
Marketing-authorisation holder
Grunenthal GmbH
Revision
16
Date of issue of marketing authorisation valid throughout the European Union
15/05/2009
Contact address
Zieglerstrasse 6
52078 Aachen
Germany

Product information

21/09/2021 Qutenza - EMEA/H/C/000909 - N/0053

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Anesthetics

Therapeutic indication

Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.

Assessment history

Related content

How useful was this page?

Add your rating